These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 3068767)

  • 1. Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma.
    Foote JE; Crawford ED
    Semin Urol; 1988 Nov; 6(4):291-302. PubMed ID: 3068767
    [No Abstract]   [Full Text] [Related]  

  • 2. Maximal androgen blockade versus total androgen suppression.
    Dumez H; Van Poppel H; Baert L; Paridaens R
    Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal management of advanced adenocarcinoma of the prostate.
    Miles BJ
    Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839
    [No Abstract]   [Full Text] [Related]  

  • 4. Maximal androgen ablation: a review.
    Miles BJ; Babiarz J
    Henry Ford Hosp Med J; 1992; 40(1-2):114-7. PubMed ID: 1428961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].
    Gorski J; Böhm WD; Illig HD; Koch R
    Urologe A; 1988 Sep; 27(5):287-90. PubMed ID: 3051628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of the concept of total androgen ablation in the treatment of prostate cancer.
    Schulze H; Isaacs JT; Coffey DS
    Prog Clin Biol Res; 1987; 243A():1-19. PubMed ID: 3309968
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
    Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
    Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
    Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
    J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 10. [Review of phase III clinical trials on combined anti-androgen therapies in patients with metastasized prostatic cancer].
    Denis L; Dalesio O; Murphy G
    Prog Urol; 1993 Feb; 3(1):75-85. PubMed ID: 8485599
    [No Abstract]   [Full Text] [Related]  

  • 11. Anemia in patients on combined androgen block therapy for prostate cancer.
    Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
    Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F; Pace M
    In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined androgen blockade: an update.
    Klotz L
    Urol Clin North Am; 2006 May; 33(2):161-6, v-vi. PubMed ID: 16631454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proton hypophysectomy and subtotal body irradiation in combined treatment of stage IV prostate cancer].
    Aleksandrov VP; Kondrat'eva EA; Karelin MI; Konnov BA; Zharinov GM; Metelev VV; Pecherskiĭ AV
    Urologiia; 1999; (6):26-8. PubMed ID: 16859000
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined castration and androgen blockade therapy in prostate cancer. Conclusions.
    Denis L; Mettlin C
    Cancer; 1990 Sep; 66(5 Suppl):1086-9. PubMed ID: 2203520
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
    Schulman CC; Wildschutz TP
    Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
    [No Abstract]   [Full Text] [Related]  

  • 19. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.